University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

I-Chow Hsu, M.D.

Radiation cancer specialist

Dr. I-Chow (Joe) Hsu is a radiation oncologist with special expertise in brachytherapy, a form of radiotherapy where a radioactive source is placed inside or next to the area requiring treatment such as localized prostate cancer. Hsu has special research interests in the application of brachytherapy and hyperthermia in genitourinary and gynecologic cancers. He is an active member of numerous professional medical societies including the American Society for Therapeutic Radiology, American Brachytherapy Society and Society for Thermal Medicine. He also chairs the brachytherapy committee of the Radiation Therapy Oncology Group.

Hsu earned a medical degree at the Johns Hopkins School of Medicine and completed a residency in radiation oncology at Columbia-Presbyterian Medical Center in New York. He is an associate professor of radiation oncology at the University of California, San Francisco. Hsu is certified in radiation oncology by the American Board of Radiology.

Clinics

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Conditions & Treatments

More about I-Chow Hsu

Additional Languages

Chinese
Mandarin

Education

John Hopkins School of Medicine 1991

Residencies

San Bernadino Medical Center, Transitional Intern 1992

Fellowships

Columbia-Presbyterian Medical, Radiation Oncology 1995

Selected Research and Publications

  1. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
  2. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
  3. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness CriteriaŽ Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
  4. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to drs rogers, hayes, and demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
  5. Salgaonkar VA, Prakash P, Rieke V, Ozhinsky E, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys. 2014 Mar; 41(3):033301.
  6. Nattagh K, Siauw T, Pouliot J, Hsu IC, Cunha JA. A training phantom for ultrasound-guided needle insertion and suturing. Brachytherapy. 2014 Jul-Aug; 13(4):413-9.
  7. Thomadsen BR, Erickson BA, Eifel PJ, Hsu IC, Patel RR, Petereit DG, Fraass BA, Rivard MJ. A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: executive summary. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):65-70.
  8. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9(1):42.
  9. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2014 Jan 16.
  10. Hsu IC, Hunt D, Straube, W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
  11. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
  12. Myerson RJ, Moros EG, Diederich CJ, Haemmerich D, Hurwitz MD, Hsu IC, McGough RJ, Nau WH, Straube WL, Turner PF, Vujaskovic Z, Stauffer PR. Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring. Int J Hyperthermia. 2014 Feb; 30(1):1-5.
  13. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
  14. Salgaonkar VA, Rieke V, Ozhinsky E, Prakash P, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MRI-guided endorectal high intensity focused ultrasound ablation array. J Acoust Soc Am. 2013 Nov; 134(5):4180.
  15. Pinnaduwage DS, Cunha JA, Weinberg V, Krishnamurthy D, Nash M, Hsu IC, Pouliot J. A dosimetric evaluation of using a single treatment plan for multiple treatment fractions within a given applicator insertion in gynecologic brachytherapy. Brachytherapy. 2013 Sep-Oct; 12(5):487-94.
  16. Hsu IC, Hunt D, Straube W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric analysis of radiation therapy oncology group 0321: The importance of urethral dose. Pract Radiat Oncol. 2014 Jan-Feb; 4(1):27-34.
  17. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 1; 119(11):1999-2004.
  18. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
  19. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206.
  20. Siauw T, Cunha A, Berenson D, Atamturk A, Hsu IC, Goldberg K, Pouliot J. NPIP: A skew line needle configuration optimization system for HDR brachytherapy. Med Phys. 2012 Jul; 39(7):4339-46.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.